Anti­platelet therapy in (cardio)vascular disease

[1]  J. T. ten Berg,et al.  The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up , 2011, Thrombosis and Haemostasis.

[2]  J. T. ten Berg,et al.  A case–control study on platelet reactivity in patients with coronary stent thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[3]  V. Deneer,et al.  Esomeprazole but Not Pantoprazole is Associated with Lower Plasma Concentrations of Clopidogrel's Active Metabolite , 2011, The Annals of pharmacotherapy.

[4]  P. D. de Groot,et al.  The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. , 2011, Blood.

[5]  Junmei Chen,et al.  Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. , 2010, Blood.

[6]  C. Hirschhäuser,et al.  Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.

[7]  A. de Boer,et al.  CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. , 2010, European heart journal.

[8]  F. Rosendaal,et al.  The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE–Platelets project , 2010, Journal of thrombosis and haemostasis : JTH.

[9]  V. Deneer,et al.  Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.

[10]  A. de Boer,et al.  Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation , 2010, Pharmacogenetics and genomics.

[11]  P. D. de Groot,et al.  Staphylococcal superantigen‐like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibα and αIIbβ3 , 2009, Journal of thrombosis and haemostasis : JTH.

[12]  F. Leebeek,et al.  Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions , 2009, Circulation. Cardiovascular genetics.

[13]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[14]  P. Mannucci,et al.  Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. , 2009, Blood.

[15]  A. Franx,et al.  Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome , 2006, Journal of thrombosis and haemostasis : JTH.

[16]  P. D. de Groot,et al.  A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. , 2005, Blood.